Sales of Leqembi® totaled 23.1 billion yen in the second quarter 2025
The results included a one-time stockpiling effect in the Chinese market of around JPY 5.3 billion in response to the risk of tariffs. Total global sales excluding the stockpiling effect were approximately JPY 17.8 billion corresponding to royalty revenue of about SEK 125 million.
BioArctic's report for the second quarter 2025 will be published on August 28 at 08:00 a.m. CET.
This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact person below, on July 31, 2025, at 12:00 CET.
For further information, please contact: Oskar Bosson, VP Communications and Investor RelationsE-mail: oskar.bosson@bioarctic.com Telephone: +46 704 107 180
About lecanemab (Leqembi®)
Lecanemab is the result of a strategic research alliance between BioArctic and Eisai. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). Lecanemab is approved in 46 countries including the U.S., Japan, China, and the European Union for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD), and is under regulatory review in 10 countries
Since July 2020, Eisai's Phase 3 clinical study (AHEAD 3-45) with lecanemab in individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. The study was fully recruited in October 2024. AHEAD 3-45 is a four-year study conducted as a public-private partnership between Eisai, Biogen and the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy.
About the collaboration between BioArctic and Eisai
Since 2005, BioArctic has a long-term collaboration with Eisai regarding the development and commercialization of drugs for the treatment of Alzheimer's disease. The most important agreements are the Development and Commercialization Agreement for the lecanemab antibody, which was signed 2007, and the Development and Commercialization agreement for the antibody Leqembi back-up for Alzheimer's disease, which was signed 2015. In 2014, Eisai and Biogen entered into a joint development and commercialization agreement for lecanemab. Eisai is responsible for the clinical development, application for market approval and commercialization of the products for Alzheimer's disease. BioArctic has the right to commercialize lecanemab in the Nordic region and is currently preparing for commercialization in the Nordics together with Eisai. BioArctic has no development costs for lecanemab in Alzheimer's disease and is entitled to payments in connection with sales milestones as well as royalties on global sales.
About BioArctic AB
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) – the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with BioArctic's partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit www.bioarctic.com.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/bioarctic/r/sales-of-leqembi--totaled-23-1-billion-yen-in-the-second-quarter-2025,c4212918
The following files are available for download:
https://mb.cision.com/Main/9978/4212918/3595601.pdf
Sales of Leqembi® totaled 23.1 billion yen in the second quarter 2025
View original content:https://www.prnewswire.co.uk/news-releases/sales-of-leqembi-totaled-23-1-billion-yen-in-the-second-quarter-2025--302518553.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
What if the dollar has bottomed?
-- A recent rebound in the U.S. dollar may mark the end of its year-to-date slide, potentially easing pressure on European equities and resetting key assumptions across global markets. The dollar, down around 10% from January highs, has recently bounced following U.S. trade agreements with Japan and the EU. Barclays analysts say this move could reflect the early stages of a broader shift, particularly as speculative positioning against the dollar looks stretched and U.S. earnings and macro data remain firm. The rally in the euro, driven more by capital flows than interest rate differentials, has been a drag on European earnings, especially for exporters. Barclays' FX strategists expect the euro to weaken gradually, forecasting EUR/USD to fall toward 1.13. That shift would reverse some of the eurozone's year-to-date 'exorbitant benefit' from dollar weakness, which had exacerbated the impact of deteriorating terms of trade due to tariffs. European stocks have lagged U.S. peers in part due to this FX dynamic. Barclays says the stronger euro has hit corporate earnings harder than tariffs, contributing to a wave of EPS downgrades in export-heavy sectors. But a dollar turnaround may offer some relief, with the potential to put a floor under European earnings estimates. Medium-term risks remain. Concerns around Federal Reserve independence and potential rate convergence in 2026, especially if German or EU growth surprises to the upside — could limit sustained dollar strength. Still, Barclays concludes that FX is no longer a one-way bet. If the dollar has in fact bottomed, it would mark a meaningful shift in global equity drivers, the brokerage said. Related articles What if the dollar has bottomed? After soaring 149%, this stock is back in our AI's favor - & already +25% in July If Powell goes, does Fed trust go with him?
Yahoo
20 minutes ago
- Yahoo
Liverpool drop MASSIVE hint that Alexander Isak deal is closer
Liverpool are reported to have been turned down by Newcastle in their first attempt to sign Alexander Isak. An official approach fell short of the Geordies' valuation - and Eddie Howe has been struggling to line up a successor. Those reports were swiftly followed up with claims from trusted journalists that Liverpool wouldn't be back. 🔴 Shop the LFC 2025/26 adidas home range Shop the LFC Store 🚨2025/26 LFC x adidas range🚨 LFC x adidas Shop the goalkeeper range today LFC x adidas Shop the new adidas range today! Newcastle's were emphatic in their refusal to do business and that was that. But there are some clues regarding this deal that all might not be what it seems. 🔴 Shop the LFC 2025/26 adidas away range One hint may well lie with Darwin Nunez. Al-Hilal intending to add Nunez Later on Friday it transpired from sources including Saudi insider Hamad al-Swilhy that Al-Hilal were pressing on with their attempts to sign Darwin from Liverpool. Simone Inzaghi - the Saudi Pro League giants' new manager - wants the Uruguayan frontman as his new striker. And all summer long it has appeared inevitable that Nunez could be leaving. If Liverpool were truly not intending to replace Darwin with Isak before the end of summer - then these rumours could be shut down pretty handily. But it remains the case that Nunez is likely to go. Liverpool won't leave themselves short Cast your mind back to last summer. Liverpool triggered Martin Zubimendi's release clause - but the deal fell apart when the player rejected the move. Richard Hughes was then criticised for neglecting to sign a replacement; the Reds instead went into the season with Ryan Gravenberch as their No1 pick in defensive midfield. The mantra at Anfield was that it was better to sign NO player than the WRONG player. We can safely assume that the stance remains the same. Liverpool will not buy a second choice. © IMAGO - Alexander Isak Liverpool If Isak doesn't come, why sell Nunez? They will either persist in their attempt to sign a priority target or else stick with what they've got. The indications are that Darwin will be sold - meaning a new No9 will certainly be required. And given Liverpool's previous conduct - if Isak is off the menu then they won't move for a different striker. That would mean Hugo Ekitike being Arne Slot's ONLY option in the centre-forward position next season before 'false nines' are considered.
Yahoo
an hour ago
- Yahoo
Intertek Group First Half 2025 Earnings: EPS: UK£0.99 (vs UK£0.88 in 1H 2024)
Intertek Group (LON:ITRK) First Half 2025 Results Key Financial Results Revenue: UK£1.67b (flat on 1H 2024). Net income: UK£158.2m (up 12% from 1H 2024). Profit margin: 9.5% (up from 8.5% in 1H 2024). EPS: UK£0.99 (up from UK£0.88 in 1H 2024). AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. All figures shown in the chart above are for the trailing 12 month (TTM) period Intertek Group Earnings Insights Looking ahead, revenue is forecast to grow 4.7% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Professional Services industry in the United Kingdom. Performance of the British Professional Services industry. The company's shares are down 6.1% from a week ago. Valuation If you are seeking undervalued stocks, our analysis of 6 valuation measures indicates Intertek Group could be a good place to look. Discover what analysts are forecasting and how the current share price shapes up by clicking here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
